BridgeBio Pharma, Inc.: financing cash flow
Financing cash flow for BridgeBio Pharma, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All BridgeBio Pharma, Inc. financial histories
What this measure means
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
Exact concept: us-gaap:NetCashProvidedByUsedInFinancingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 359,293,000 | USD | 2026-02-24 | 10-K · 0001743881-26-000009 |
| 2024-01-01 | 2024-12-31 | 748,457,000 | USD | 2026-02-24 | 10-K · 0001743881-26-000009 |
| 2023-01-01 | 2023-12-31 | 451,535,000 | USD | 2026-02-24 | 10-K · 0001743881-26-000009 |
| 2022-01-01 | 2022-12-31 | -13,134,000 | USD | 2025-02-20 | 10-K · 0000950170-25-024119 |
| 2021-01-01 | 2021-12-31 | 736,446,000 | USD | 2024-02-22 | 10-K · 0000950170-24-018811 |
| 2020-01-01 | 2020-12-31 | 447,189,000 | USD | 2023-02-23 | 10-K · 0000950170-23-004145 |
| 2019-01-01 | 2019-12-31 | 398,792,000 | USD | 2022-02-25 | 10-K · 0000950170-22-002030 |
| 2018-01-01 | 2018-12-31 | 501,548,000 | USD | 2021-02-25 | 10-K · 0001564590-21-008969 |
| 2017-01-01 | 2017-12-31 | 112,983,000 | USD | 2020-03-03 | 10-K · 0001564590-20-008260 |
Related financial histories
- BridgeBio Pharma, Inc.: total assets
- BridgeBio Pharma, Inc.: total liabilities
- BridgeBio Pharma, Inc.: stockholders equity
- BridgeBio Pharma, Inc.: cash and cash equivalents
- BridgeBio Pharma, Inc.: operating cash flow
- BridgeBio Pharma, Inc.: capital expenditure payments
- BridgeBio Pharma, Inc.: contract revenue excluding tax
- BridgeBio Pharma, Inc.: investing cash flow
- BridgeBio Pharma, Inc.: retained earnings or deficit
- BridgeBio Pharma, Inc.: basic weighted-average shares
- BridgeBio Pharma, Inc.: diluted weighted-average shares
- BridgeBio Pharma, Inc.: basic earnings per share
- BridgeBio Pharma, Inc.: diluted earnings per share
- BridgeBio Pharma, Inc.: income tax expense or benefit
- BridgeBio Pharma, Inc.: net property, plant and equipment
- BridgeBio Pharma, Inc.: share-based compensation expense
- BridgeBio Pharma, Inc.: operating income or loss
- BridgeBio Pharma, Inc.: current assets
- BridgeBio Pharma, Inc.: interest expense
- BridgeBio Pharma, Inc.: current liabilities
- BridgeBio Pharma, Inc.: current accounts payable
- BridgeBio Pharma, Inc.: net finite-lived intangible assets
- BridgeBio Pharma, Inc.: net current accounts receivable
- BridgeBio Pharma, Inc.: common-stock repurchase payments
- BridgeBio Pharma, Inc.: operating expenses
- BridgeBio Pharma, Inc.: cost of revenue
- BridgeBio Pharma, Inc.: selling, general and administrative expense
- BridgeBio Pharma, Inc.: research and development expense
Inspect the source
- Entity
- BridgeBio Pharma, Inc. / CIK 0001743881
- Captured
- 2026-09-21T17:28:42.220Z
- SEC response SHA-256
33035a520f449c0cb2294b38d131bf0a0a81b13ec488fea5d3f482b6f0389c9c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001743881.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))